Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Actuarial Approach01:20

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Creating Evidence-Based Ratings and Life Expectancies Medical Impairments.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

The Smoking Dilemma: A Technical Deep Dive.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Biological Clocks: Ready for Prime Time?

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Identifying Benzodiazepine Abuse: A Report of 3 Cases.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Between Fear and Adoption: The AI Paradox in Medico-Legal Practice Among National Insurance Physicians.

Journal of insurance medicine (New York, N.Y.)·2026
Same journal

Prostate Cancer - 20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration and Cohort Entry Period: A Systematic Review of 648,114 cases for Diagnosis Years 1975-2022.

Journal of insurance medicine (New York, N.Y.)·2026

Related Experiment Videos

GLP-1 Therapies and Mortality Risk: Implications for Life Insurers.

Gina C Guzman, Tristan Walsh

    Journal of Insurance Medicine (New York, N.Y.)
    |June 17, 2026
    PubMed
    Summary

    Glucagon-like peptide-1 (GLP-1) receptor agonists show potential for significant mortality improvement in non-diabetic conditions. Insurers can leverage these findings for underwriting, but adherence is key to realizing long-term benefits.

    Keywords:
    Electronic health records (EHRs)GLP-1Glucagon-like peptide-1 agonistmetabolic riskmorbiditymortalityproduct developmentunderwriting

    Related Experiment Videos

    Area of Science:

    • Pharmacology and Therapeutics
    • Public Health and Epidemiology
    • Insurance and Risk Management

    Background:

    • Glucagon-like peptide-1 (GLP-1) receptor agonists, initially for diabetes, now show promise for non-diabetic conditions.
    • These drugs offer potential improvements in mortality and morbidity, attracting insurer interest.
    • Key areas of interest for insurers include mortality improvement, medical underwriting, and new product development.

    Purpose of the Study:

    • To quantify the potential annual mortality improvement driven by GLP-1 receptor agonists.
    • To explore the implications of GLP-1 drugs for the insurance industry, particularly in underwriting.
    • To identify challenges and opportunities related to GLP-1 drug adoption in risk assessment.

    Main Methods:

    • Large-scale mortality study to estimate the impact of GLP-1 drugs.
    • Analysis of potential mortality improvement over a 20-year period.
    • Consideration of factors influencing long-term benefits, such as patient adherence.

    Main Results:

    • GLP-1 drugs are estimated to drive 0.2%-0.5% annual mortality improvement.
    • These benefits are projected to be realized over a 20-year timeframe.
    • Low patient adherence may limit the achievement of long-term mortality benefits.

    Conclusions:

    • GLP-1 drugs present significant opportunities for mortality improvement and innovation in insurance underwriting.
    • Electronic health records are crucial for accurate metabolic risk assessment in underwriting.
    • Variations in individual risk profiles necessitate nuanced program design and application for GLP-1 therapies.